{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-032885","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2024-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.030632+00:00","generated_at":"2026-05-31T21:40:14.082632+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"STRATA pre-announces Q2 revenue $8.0M-$8.4M; XTRAC base down, TheraClear X up","bullets":["Preliminary Q2 2024 total revenue range: $8.0M - $8.4M.","Domestic XTRAC installed base fell from 907 (Q1) to 881 (Q2) per device realignment.","TheraClear X installed base grew from 104 (Q1) to 117 (Q2).","Cash, cash equivalents, and restricted cash totaled $6.8M at quarter end.","Full Q2 2024 results expected to be reported on August 14, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-032885","json":"https://secwatch.observer/filing/0001140361-24-032885.json","markdown":"https://secwatch.observer/filing/0001140361-24-032885.md","text":"https://secwatch.observer/filing/0001140361-24-032885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124032885/0001140361-24-032885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124032885/ef20032281_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:40:14.082632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}